Pricing of PBS Items

Page last updated: 1 August 2017

The information in this section of the PBS website relates to the ex-manufacturer prices of brands of pharmaceutical item subsidised under the PBS.  It is intended to provide guidance on the processes used to agree and review ex-manufacturer prices for pharmaceutical benefits, including on statutory price reductions applied under Division 3A of the National Health Act 1953.

Information on the operations of price disclosure is available in Pricing Matters.

Information on the mark-ups and fees that apply to pharmaceutical benefits when they are supplied in different settings (eg. community pharmacy, public hospital, private hospital) or under different PBS programs (eg. general schedule, Section 100 Highly Specialised Drugs Program, Section 100 Efficient Funding of Chemotherapy) is available in the Explanation of PBS Pricing.


For queries related to PBS pricing please email the Department through the Pricing Section.

Arrangements following cessation of the Pharmaceutical Benefits Pricing Authority

  • Sponsors of submissions to the November 2014 or later PBAC meetings who are required to provide Cost of Goods Information must provide that information at the time of submission to PBAC; and
  • There will be no changes to the current processes for sponsors seeking price increases for currently listed PBS medicines.

Primary Sources

Explanatory materials and forms

Historical references